Edwards temporarily freezes enrollment in mitral valve program

Candace Stuart | | Cardiovascular Business | Structural Heart Disease

Edwards Lifesciences put enrollment into a program using its FORTIS transcatheter valve replacement therapy on hold, announcing that it wants to investigate reports of valve thrombus.

The device, which is investigational only, was implanted in more than 20 patients with symptomatic mitral regurgitation who were either compassionate cases or enrolled in a high-risk registry. The FORTIS valve incorporates treated bovine pericardial tissue on a cloth-covered, self-expanding frame, a design that is intended to minimize paravalvular leak.

The heart team at St. Thomas' Hospital in London performed the first three cases in February and March of 2014. In addition, a patient treated in Bern, Switzerland, received the device. The researchers shared their experiences about those four cases at EuroPCR in 2014, where they reported that three patients died between four and 76 days after the procedure.

Edwards is working with researchers to investigate the thrombus issue further. “While it is still very early in the program, and we anticipated that optimizing this therapy would be challenging, we are continuing to learn which patients may benefit,” the company announced in a news release.

Candace Stuart, Contributor

Related Content

TAVR patients with moderate or greater TR may face increased risks
Robotic heart surgery represents a key step forward for SS Innovations
Late-breaking clinical trials announced for New York Valves 2025
Q&A: Cardiologist and EARLY TAVR co-author questions study’s execution
Balloon-expandable, self-expanding TAVR valves associated with comparable long-term outcomes
‘A compelling alternative’: Polymer heart valve receives first commercial approval of its kind

Around the web

Health Exec
Tom Price: Medical residency slots need to expand to combat physician shortages

Tom Price, MD, former secretary of Health and Human Services (HHS), said one way to address the growing shortage of physicians is to expand medical resident positions, but these are tied to Medicare spending so alternative means may be needed.

Health Imaging
Tariffs will have a significant impact on the nuclear imaging supply chain in the US

"Domestic radiopharmaceutical suppliers, who receive isotopes from abroad, would be impacted by price changes and uncertainty caused by additional tariffs,” SNMMI President Cathy Cutler, PhD, wrote in a letter to the U.S. Department of Commerce this week.

Radiology Business
U.S. iodine contrast supply may not be subject to proposed 25% tariffs

If President Trump initiates a 25% tariff against pharmaceuticals imported from Ireland, it might impact the price for X-ray iodine contrast agents in the U.S. depending what rules are put in place.